{"product_id":"neurenpharma-five-forces-analysis","title":"Neuren Pharmaceuticals Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals faces moderate supplier and buyer power, high threat from substitutes and regulatory hurdles, and low threat of new entrants due to specialized R\u0026amp;D—positioning its competitive dynamics as niche but vulnerable to clinical setbacks.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Neuren Pharmaceuticals’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren depends on a few specialized contract manufacturing organizations (CMOs) for trofinetide and NNZ-2591; as of 2025 only ~4–6 CMOs globally hold the required GMP certifications and peptide\/complex-synthesis capability, limiting switching options.\u003c\/p\u003e\n\u003cp\u003eThis supplier concentration gives CMOs moderate pricing and scheduling leverage—Neuren cited CMO-related COGS variability of ±8–12% in its 2024 annual report—and single-supplier runs could delay supply by 6–12 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Single-Source API Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren relies on single-source active pharmaceutical ingredient suppliers to maintain batch-to-batch consistency for FDA and EMA filings; switching a supplier can cost $0.5–3M and take 6–18 months for validation and regulatory resubmissions. This dependence raises supplier leverage in long-term contracts, often forcing fixed-price or volume commitments that reduce Neuren’s bargaining power and can increase COGS by 5–12% per product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Clinical Trial Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuren depends on specialized clinical research organizations (CROs) for late-stage trials in Phelan-McDermid and Pitt-Hopkins syndromes; top CROs held ~40–60% price premium in 2024 for rare-disease programs due to high demand. \u003c\/p\u003e\n\u003cp\u003eLimited patient pools make CROs with established site networks scarce assets, pushing contracting leverage to suppliers and raising trial costs by an estimated 15–25% versus common-indication studies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Acadia Pharmaceuticals licensing deal gives Acadia the commercial engine for DAYBUE in North America, effectively supplying Neuren with market access and distribution capacity Neuren lacks.\u003c\/p\u003e\n\u003cp\u003eLicensing terms (fixed royalties and milestones) were central to Neuren’s reported FY2024 revenue of NZD 31.2m, so Acadia’s control over launch, pricing, and promotion directly shapes Neuren’s cash flow.\u003c\/p\u003e\n\u003cp\u003eBecause these terms are long-dated and hard to renegotiate, Acadia wields high supplier bargaining power that can affect net margin and growth pacing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcadia provides N. American commercialization\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue NZD 31.2m tied to deal\u003c\/li\u003e\n\u003cli\u003eFixed royalties\/milestones limit Neuren leverage\u003c\/li\u003e\n\u003cli\u003eHigh influence on pricing, launch, uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Labor Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe supply of scientists and regulatory experts for orphan drugs is tight; globally there were an estimated 32,000 rare-disease R\u0026amp;D roles in 2024, concentrated in the US and EU.\u003c\/p\u003e\n\u003cp\u003eAs Neuren scales, it competes with Big Pharma offering salaries 20–40% higher; median regulatory director pay hit ~USD 220,000 in 2024, pushing Neuren’s OPEX up.\u003c\/p\u003e\n\u003cp\u003eThis scarcity increases bargaining power for top talent on pay, equity and flexible benefits, raising hiring lead times and retention costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~32,000 rare-disease R\u0026amp;D roles (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory director median pay ≈ USD 220,000 (2024)\u003c\/li\u003e\n\u003cli\u003eBig Pharma premium: +20–40% vs small biotech\u003c\/li\u003e\n\u003cli\u003eHigher OPEX, longer hire times, greater retention spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier power: limited CMOs, costly API swaps, CRO premiums \u0026amp; talent squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: 4–6 qualified CMOs worldwide limit switching, causing COGS variability of ±8–12% and 6–12 month supply delays; single-source API swaps cost $0.5–3M and 6–18 months; CROs charge 40–60% premium for rare-disease trials, raising trial costs 15–25%; Acadia’s FY2024-linked licensing (NZD 31.2m) gives it strong control over launch\/pricing; talent scarcity (≈32,000 roles) raises OPEX.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified CMOs\u003c\/td\u003e\n\u003ctd\u003e4–6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS variability\u003c\/td\u003e\n\u003ctd\u003e±8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI switch cost\/time\u003c\/td\u003e\n\u003ctd\u003e$0.5–3M \/ 6–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO premium\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial cost uplift\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcadia-linked revenue\u003c\/td\u003e\n\u003ctd\u003eNZD 31.2m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease R\u0026amp;D roles\u003c\/td\u003e\n\u003ctd\u003e≈32,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Neuren Pharmaceuticals that uncovers competitive drivers, buyer\/supplier influence, entry barriers, substitute threats, and strategic vulnerabilities shaping its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary tailored to Neuren Pharmaceuticals—ideal for quick investor decisions and slide-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Payor Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US, large insurers and government payors (Medicaid) dominate purchasing for orphan drugs, giving them strong leverage over Neuren’s DAYBUE pricing and access; Medicare Part D\/Medicaid influence affects ~60–70% of insured patients with rare disease claims. Payors set reimbursement and formulary placement, often demanding discounts and step edits. With DAYBUE’s list price around $150,000\/year (2025 list estimates), insurers impose strict prior authorization and utilization management to control spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRole of Specialized Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren’s commercial fate depends on regional partners like Acadia, who in 2025 handled U.S. launch efforts and control the sales channel, influencing marketing spend and prescribing focus; Acadia’s 2024 agreement gave it ~60% of U.S. net profits, showing material profit-share leverage. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups for Rett syndrome strongly shape demand: over 70% of families consult advocacy resources when choosing treatments, so their endorsement can drive uptake of Neuren’s trofinetide (as of 2024 trofinetide global net sales reached US$28m in initial markets).\u003c\/p\u003e\n\u003cp\u003eThese groups influence regulators and payors by lobbying and real-world data campaigns; advocacy-led registries helped secure compassionate-use and reimbursement in 3 countries by 2025.\u003c\/p\u003e\n\u003cp\u003eNeuren must sustain funded partnerships and co‑sponsor registries to keep trial enrollment high—Rett trials relying on advocacy channels report 30–50% faster recruitment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Prescription Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa small group of specialized pediatric neurologists in the us and eu act as gatekeepers for neuren therapies so prescribing by a few key opinion leaders can sway uptake niche indications these clinicians demand strong phase iii evidence multi-year safety data giving them high bargaining power over pricing formulary access post-marketing study requirements.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOutside the US, nationalized systems (e.g., NHS UK, France, Germany) act as monopsony buyers with high price sensitivity; Neuren must demonstrate cost-effectiveness versus supportive care, often via health technology assessments (HTAs) that press down prices.\u003c\/p\u003e\n\u003cp\u003eThese negotiations shrink international margins—Neuren’s FY2024 revenue split showed ~60% US sales higher-margin vs 40% lower-margin ex-US sales, with European net prices ~25–40% below US list prices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonopsony buyers: NHS, other national payers\u003c\/li\u003e\n\u003cli\u003eHTA-driven cuts: European prices 25–40% below US\u003c\/li\u003e\n\u003cli\u003eNeuren FY2024: ~60% US, ~40% ex-US revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Dominate Neuren Pricing: US Payors, Acadia Control Access \u0026amp; 60–40 Revenue Split\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (insurers, gov payors, HTAs) hold high leverage over Neuren’s pricing and access—US payors influence ~60–70% of rare-disease claims; 2025 DAYBUE list ~US$150,000\/yr faces strict prior auth and discounts. Regional partner Acadia controlled ~60% of U.S. net profits (2024 deal), shifting commercial power. European HTAs cut net prices ~25–40% vs US; FY2024 revenue split ~60% US \/ 40% ex-US.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDAYBUE list (est 2025)\u003c\/td\u003e\n\u003ctd\u003eUS$150,000\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayor influence on claims\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS vs ex‑US revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e60% \/ 40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU price reduction vs US\u003c\/td\u003e\n\u003ctd\u003e25–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcadia profit share (2024 deal)\u003c\/td\u003e\n\u003ctd\u003e~60% US net\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eNeuren Pharmaceuticals Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Neuren Pharmaceuticals you’ll receive immediately after purchase—no surprises, no placeholders. The document covers threat of new entrants, bargaining power of suppliers and buyers, threat of substitutes, and industry rivalry with specific evidence and scoring. It’s professionally formatted, ready for download and use the moment you buy. You’re previewing the final deliverable in full.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747166761337,"sku":"neurenpharma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/neurenpharma-five-forces-analysis.png?v=1772195571","url":"https:\/\/growthsharematrix.com\/products\/neurenpharma-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}